Came across the article in a news daily -
To what extent the chinese competition likely to impact the story for Laurus?
2 Likes
Some twitter user shared this. Can somebody throw light on how can a person get such information?? I googled for bakuchiol and I found that it’s a derivative from a plant. Then how the laurus can manufacture it??
3 Likes
From IPO prospectus:
http://www.investmentbank.kotak.com/downloads/lauruslabslimited-prospectus.pdf
18 Likes
Anyone has idea on whether Laurus supply Revlimid API’s to Natco ?
Just in: USFDA approves Kalydeco (#Ivacaftor) as first & only CFTR modulator to treat eligible infants with cystic fibrosis (CF) as early as four months of age
#lauruslabs
Got this info from a Twitter user… does anyone has the info of the market size and key producers of the drug and laurus partnerships with them??
4 Likes
According to the Cystic Fibrosis Foundation Patient Registry, in the United States:
- More than 30,000 people are living with cystic fibrosis (more than 70,000 worldwide).
- Approximately 1,000 new cases of CF are diagnosed each year.
- More than 75 percent of people with CF are diagnosed by age 2.
- More than half of the CF population is age 18 or older.
1 Like
Its produced by Vertex Pharmaceuticals. Laurus Labs holds certain patent related to this but not sure how it exactly is Laurus involved. And how it benefits.
2 Likes
And Vertex is doing very good there. I guess this might go extremely good for Laurus as well… Check attachment.
Scan 28-Sep-2020.pdf (41.2 KB)
1 Like
Laurus labs merged it’s two subsidiaries in the usa. Laurus synthesis and laurus generics
I was trying to understand the IP risk with laurus venturing into Formulations. The following sentence is fully written from Laurus point of view. Almost appears to convey ‘No Problem!’. Can those in the industry give their viewpoint.
Disclosure - invested at ~ 1100 levels
This assessment of the situation might have been relevant a decade ago, but the industry has changed: stakeholders do not recognize the same boundaries as before, where companies used to stick to their areas of expertise. To give you a concrete example, the number of legal actions between two originators today are significant when compared to the number of trials between originators and generics companies. In the same way, generics companies are trying the climb up the value chain, while originators have been expanding their business model to the generics field. There is not a single company operating at the global scale that is not diversifying its business model and venturing into new verticals to better benefit from emerging market trends. I believe that our API customers understand these dynamics, as they follow the same approach when it comes to the diversification of their own revenue stream.
At the end of the day, if Laurus is able to offer a better API at a lower price and with a greater capacity than a given competitor exclusively focus on APIs, I have no doubts that our customers will remain loyal to our offering – even if we eventually become one of their competitors on the formulation side.
10 Likes
Everyone is saying laurus labs is going in divis labs way and its next divis but as I can see its adopting dr Reddy labs strategy by diversifying into formulations and other verticals. The divis is solely a pure play api company.
4 Likes
https://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=540222&qtrid=107.00
Laurus labs put up a BSE notification today. Pledged shares down to just 16 percent. Please delete if already mentioned earlier. Just noticed it today on the website
4 Likes
Has ambit capital existed from lauruslabs?? I can’t find their name in the September share holding data. Could someone throw some light on it??earlier they used to have 11 %.
Laurus labs made a proposal to invest 300 crores in HYDERABAD’s genome vally.
2 Likes
Looks like this FDF capex is in addition to what they announced in 1Q21 earnings call.
“Laurus Labs has also announced the setting up of a formulation facility. The company plans to invest ₹300 crore in two phases of ₹150 crore each. Laurus Labs has its R&D facility in IKP Knowledge Park, Hyderabad and also operates six manufacturing facilities in Visakhapatnam, Andhra Pradesh.”
3 Likes
Revenue growth of 60% and PAT growth of 325% in Q2 FY21
Q2 FY21 Revenues up 60%
Q2 FY21 EBITDA at ₹ 378 crs up 172%, Margins at 33%
Q2 FY21 PAT at ₹ 242 crs, margins at 21%
10 Likes
Going through the investor presentation
What does “in-licensed” in the following mean in page 5 under Generic FDF?
“Commenced marketing of in-licensed products in the USA to
leverage front-end capabilities”
I read this in press release
“Commenced marketing of products of other manufactures by leveraging our front end”
Is this like retail? Selling products of other companies?? 
Edit: This last edit should complete the story and answer my own questions
Found this in Q42020. It would still be nice if someone confirmed this is part and parcel of Contract manufacturing biz.
2 Likes
Q2 concall notes
- Expect growth to continue & there are no one-off numbers
- Expect future quarters to be better than Q2
- Gross & EBITDA margin will be maintained
- Biggest order in cos history – which is NOT dependent on covid
- Will release the entire pledge soon
Bullish on their prospects based on excellent order book
Increased their capex plans from 700cr. to 1200cr. over the next 2 years.
New API, FDF and Custom Synthesis plants
30% increase in total API capacity.
80% increase in FDF.
New plant and R&D Facility to focus on custom synthesis which has been growing by 30%. (in Q1 launched a new subsidiary to increase focus on synthesis).
All the green field expansion have turned Cash positive in FY20 with near maximum utilization
Plan to spend 1400-1500 crs on brown field and green field capex with 40% for APIs, 40% for formulations and 20% for CRAMS…
EU - CDMO for non-ARV working very well
4% revenue spent on R&D in H1 FY21
Expect life time highest ARV sales in current fy
Healthy CDMO order book
Synthesis - YoY 36% growth / R&D capex of 60cr - will start contributing to topline in next FY
Customers are not stocking APIs due to covid next wave
Robust growth in Other API segment to continue on the back of higher order book visibility from key therapeutic segments like CVS, Anti Diabetic and PPIs
Formulations growth was led by higher LMIC Market volumes and increased
volumes from North America and EU
Capex increase of 70-80% in last 2-3 quarters is mainly due to increasing order book visibility
Expected revenue contribution change in next 2-3 years from current 60% ARV / 40% non-ARV to 50:50
30% capacity addition in APIs in next 18 months
80% capacity addition in formulation side in next 18 months
nothing new in Q2 - its just normal business as we have not added any new product or new client… so its just normal business & increased demand from current products / clients… indicates that it was not one time performance
Majority of capex will be operational by June’22 (40% API, 40% formulations, 20% synthesis)
After capex (around FY24) base will increase but % contribution will remain similar
ROCE after capex should come down but still it will be industry best (H1 ROCE was 37%)
Process innovation - currently we have 25% market share in 7 APIs / we want to have similar leadership in 15 APIs
Majority of above 15 APIs will have backend integration from formulations but not all
HIV medication :single month dispensing has moved to multi month dispensing (earlier patients were getting 30 day medicine are getting 90 day medicine now in one go to reduce their visits in these tough covid times)
Please consume above data at your risk, I may have overheard and have manipulated some inputs based on owner bias
29 Likes